Rheumatology

NCI-CCC Tumor Board Question

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?

As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...

1 Answer available

How would you manage a case of subcutaneous panniculitis-like T cell lymphoma (A/B) who is already on steroids and methotrexate for autoimmune disease?

1 Answer available

How do you counsel an early stage breast cancer patient with lupus regarding decisions on radiation?

3 Answers available

In which patients with stage IV NSCLC and PD-L1 TPS >50% plus concomitant autoimmune disease is it considered safe to give immune checkpoint blockers?

1 Answer available

Papers discussed in this category

Annals of internal medicine, 2018-01-16

Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

Rheumatology

NCI-CCC Tumor Board Question

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology